AFT new FDA approval could be a shot in the arm

AFT new FDA approval could be a shot in the arm
Analyst sentiment is positive after FDA approval of Maxigesic IV. (Image: Hyloris Pharmaceuticals)
Ben Moore
AFT Pharmaceuticals had a bump in share price on Wednesday morning following approval of its intravenous post-operative pain relief drug by the United States Food and Drug Administration.Following the announcement of the approval of Maxigesic IV, which came in overnight, the stock lifted 16 cents per share to $3.56 at the open on the New Zealand stock exchange (NZX), up from $3.40 at yesterday's close. It has since dipped to $3.50.AFT co-founder and managing director Hartley Atkinson said they were delighted to receive the second appro...

More Markets

NZ sharemarket rises on back of positive news
Markets Market close

NZ sharemarket rises on back of positive news

The S&P/NZX 50 Index closed at 13,041.9, rising 276.66 points or 2.17%

Graham Skellern 22 Nov 2024
Oceania shrinks footprint, prioritises balance sheet
Property

Oceania shrinks footprint, prioritises balance sheet

Oceania has divested four aged care facilities in the space of six months.

Gregor Thompson 22 Nov 2024
The Warehouse’s plan to come back ‘with a vengeance’
Retail

The Warehouse’s plan to come back ‘with a vengeance’

Executives face tough questions at the retailer’s AGM.

Victoria Young 22 Nov 2024
Wellington's blue sky boondoggle
Infrastructure

Pattrick Smellie: Wellington's blue sky boondoggle

Is the capital's airport serious, or is Infratil just trying to pump value?

Pattrick Smellie 22 Nov 2024